Neurocognitive profiles structure heterogeneous treatment response to bumetanide in neurodevelopmental disorders: secondary analysis of a multiple baseline single-case experimental design
European Child & Adolescent Psychiatry · 16.11.2026
DOI: 10.1007/s00787-026-03220-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Child & Adolescent Psychiatry, online erschienen am 16.11.2026. Verfasst von Lisa Geertjens und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC, N=You Neurodevelopmental Precision Center, Meibergdreef 9, Amsterda…. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Dutch national research agenda (NWA-ORC).
Abstract (Originalsprache)
We performed a secondary analysis of the Bumetanide for Developmental Disorders (BUDDI;EUDRA-CT-2020–002196-35) trial to examine whether baseline neurocognitive profiles are associated with differential behavioral and cognitive treatment response.
Participants
(7–19 years) with atypical sensory reactivity and ASD, ADHD, epilepsy, or TSC diagnoses received 6-months of bumetanide treatment (max 3.0 mg/day) within a multiple-baseline SCED. Neurocognitive functioning was assessed across multiple domains and used to derive subgroups via cluster analysis. Behavioral outcomes were captured using a parent-reported PROMset and standardized questionnaires. Linear mixed models and subgroup comparisons were used to evaluate change over time. Of 119 participants enrolled, 105 completed baseline and 85 follow-up assessments At the group level, memory improved after six months (B = 0.65, 95%CI = 0.45to0.85, pFDR < .001, d = 1.07), while processing speed decreased (B = − 0.25, 95%CI = − 0.42to − 0.07, pFDR < .001, d = − 0.49). Cluster analysis identified four neurocognitive subgroups with distinct baseline profiles and differential treatment responses: individuals with weaker functioning showed the largest memory improvements, whereas those with preserved functioning showed greater behavioral improvement alongside declines in processing speed and visuomotor integration. Across subgroups, neurocognitive and behavioral changes did not align, and correlations were small (r < 0.30). In this study, neurocognitive profiling based on a standardized test battery was associated with distinct patterns of change during treatment. The dissociation between neurocognitive and behavioral outcomes indicated domain-specific and non-linear treatment effects. These findings provide a basis for linking variability in real-world change to individual neurocognitive characteristics within a defined clinical context.
Trial registration
EudraCT (2020–002196–35) registration date 24–04-2020. Protocol: https://doi.org/10.1186/s12888-022-04033-8
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC, N=You Neurodevelopmental Precision Center, Meibergdreef 9, Amsterdam, 1105, the Netherlands.
- Emma Neuroscience Group, Department of Pediatrics, Emma Children's Hospital, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
- Amsterdam Reproduction and Development Research Institute, Amsterdam, the Netherlands.
- Emma Children's Hospital Amsterdam UMC Follow Me Program & Emma Neuroscience Group, Department of Pediatrics, Emma Children's Hospital, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
- Emma Center for Personalized Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
- Department of Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC, N=You Neurodevelopmental Precision Center, Meibergdreef 9, Amsterdam, 1105, the Netherlands. h.bruining@amsterdamumc.nl.
Förderung
- Dutch national research agenda (NWA-ORC)
Zitieren
APA
Geertjens, L., Kooper, C. C., Königs, M., Oosterlaan, J., Sprengers, J., & Bruining, H. (2026). Neurocognitive profiles structure heterogeneous treatment response to bumetanide in neurodevelopmental disorders: secondary analysis of a multiple baseline single-case experimental design. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-026-03220-2
Vancouver
Geertjens L, Kooper CC, Königs M, Oosterlaan J, Sprengers J, Bruining H. Neurocognitive profiles structure heterogeneous treatment response to bumetanide in neurodevelopmental disorders: secondary analysis of a multiple baseline single-case experimental design. European Child & Adolescent Psychiatry. 2026. doi:10.1007/s00787-026-03220-2
BibTeX
@article{Geertjens2026,
author = {Geertjens, Lisa and Kooper, Cece Constance and Königs, Marsh and Oosterlaan, Jaap and Sprengers, Jan and Bruining, Hilgo},
title = {Neurocognitive profiles structure heterogeneous treatment response to bumetanide in neurodevelopmental disorders: secondary analysis of a multiple baseline single-case experimental design},
journal = {European Child & Adolescent Psychiatry},
year = {2026},
doi = {10.1007/s00787-026-03220-2}
}
EUVIMED